Orbital metastasis from thyroid cancer: a case report and review of the literature.

Giulia Sapuppo, Federica Martorana, Elena Tirrò, Rosario Le Moli, Romilda Masucci, Lelio Baldeschi, Corrado Spatola, Antonino Belfiore, Paolo Vigneri, Gabriella Pellegriti

Journal: Annals of palliative medicine 2022;11(10):3346-3355

PMID: 35695049

Abstract

BACKGROUND

Differentiated thyroid cancer (DTC) is generally associated with an excellent prognosis. However up to 20% of DTC patients have disease events during subsequent follow-up; rarely patients present an aggressive disease with distant metastases (DM), mainly in the lung and bone. Metastases at unusual sites may also occur, generally in patients with disseminated disease. Orbital localization is rare and only few cases have been described so far.

CASE DESCRIPTION

A 36 years-old man, treated with chemo and radiotherapy during childhood for non-Hodgkin lymphoma, was referred for suspicious lymph node (LN) and multiple lung metastases. Total thyroidectomy and latero-cervical (LC) lymphadenectomy were performed: papillary thyroid cancer (PTC), 25 mm, 11/17 LN metastases; pT2N1bM1. Post-treatment total body scan with I-131 showed LN and lung uptake. Eighteen months from diagnosis he presented progressive diplopia, proptosis and right exophthalmos due to an 18 mm orbital metastasis. Hence, due to I-131 refractoriness for structural disease progression despite I-131 therapy, he started therapy with Lenvatinib for 6 months, with initial partial response followed by disease progression, and then with Cabozantinib, which he stopped after 6 months for adverse events and disease progression after therapy reduction. Currently, the patient is receiving Lenvatinib, rechallenge therapy, with disease stabilization and biochemical response. Molecular analysis, performed on both primary and relapsed tumor didn't show any significant pathogenic alteration.

CONCLUSIONS

This case of DTC with an unusual metastasis in the orbit, may suggest that patient's exposure to chemo- and radiotherapy during pediatric age might have played a role in the subsequent development of this unusually aggressive tumor, reinforcing the recommendation of long-term and intensive follow-up of these patients.

Address: Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Medical Center, Catania, Italy; Center of Experimental Oncology and Hematology, Department of Clinical and Experimental Medicine, Policlinico "G. Rodolico-San Marco" Medical Center, Catania, Italy.; Center of Experimental Oncology and Hematology, Department of Clinical and Experimental Medicine, Policlinico "G. Rodolico-San Marco" Medical Center, Catania, Italy.; Center of Experimental Oncology and Hematology, Department of Clinical and Experimental Medicine, Policlinico "G. Rodolico-San Marco" Medical Center, Catania, Italy; Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy.; Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Medical Center, Catania, Italy.; Clinical and Diagnostic Center, G.B. Morgagni, Catania, Italy.; Department of Ophthalmology, Hospital Saint Luc, Catholic University of Louvain, Brussels, Belgium.; Department of Oncological Radiotherapy, "G. Rodolico-San Marco" Medical Center, Catania, Italy.; Endocrinology, Garibaldi-Nesima Medical Center, Catania, Italy.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.